KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Non Operating Income (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Non Operating Income for 16 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 133.16% year-over-year to $1.3 million, compared with a TTM value of $3.2 million through Sep 2025, up 18.79%, and an annual FY2024 reading of $2.4 million, up 209.48% over the prior year.
  • Non Operating Income was $1.3 million for Q3 2025 at TherapeuticsMD, up from $1.2 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $131.7 million in Q2 2022 and bottomed at -$108.9 million in Q4 2022.
  • Average Non Operating Income over 5 years is $750526.3, with a median of $333000.0 recorded in 2024.
  • The sharpest move saw Non Operating Income tumbled 689.47% in 2022, then skyrocketed 2898.28% in 2024.
  • Year by year, Non Operating Income stood at $25.3 million in 2021, then tumbled by 529.54% to -$108.9 million in 2022, then surged by 100.02% to $27000.0 in 2023, then skyrocketed by 1388.89% to $402000.0 in 2024, then skyrocketed by 228.86% to $1.3 million in 2025.
  • Business Quant data shows Non Operating Income for TXMD at $1.3 million in Q3 2025, $1.2 million in Q2 2025, and $203000.0 in Q1 2025.